12:00 AM
May 18, 2009
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Clavis preclinical data

In vitro, CP-4200 increased re-constitution of normal cell function, reduced dependency of multidrug resistance, improved cellular uptake and demonstrated a rapid onset...

Read the full 88 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >